148 related articles for article (PubMed ID: 37165435)
1. Association between clinical use of lansoprazole and the risk of type 2 diabetes mellitus: a pharmacoepidemiological cohort study.
Lin MH; Wu WT; Chen YC; Lin TK; Chou YC; Sun CA
Diabetol Metab Syndr; 2023 May; 15(1):96. PubMed ID: 37165435
[TBL] [Abstract][Full Text] [Related]
2. Clinical Use of Lansoprazole and the Risk of Osteoporosis: A Nationwide Cohort Study.
Chung MH; Chen YC; Wu WT; Lin MH; Yang YJ; Hueng DY; Lin TK; Chou YC; Sun CA
Int J Environ Res Public Health; 2022 Nov; 19(22):. PubMed ID: 36430077
[TBL] [Abstract][Full Text] [Related]
3. Association between Non-Steroidal Anti-Inflammatory Drugs Use and the Risk of Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study.
Lin MH; Wu WT; Chen YC; Lu CH; Su SC; Kuo FC; Chou YC; Sun CA
J Clin Med; 2022 Jun; 11(11):. PubMed ID: 35683572
[TBL] [Abstract][Full Text] [Related]
4. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study.
Lin HC; Hsiao YT; Lin HL; Uang YS; Cheng HW; Wang Y; Wang LH
Medicine (Baltimore); 2016 Jul; 95(28):e4195. PubMed ID: 27428221
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Lin CF; Shen LJ; Wu FL; Bai CH; Gau CS
Br J Clin Pharmacol; 2012 Nov; 74(5):824-34. PubMed ID: 22364155
[TBL] [Abstract][Full Text] [Related]
6. Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study.
Chu CC; Chen YC; Lin MH; Wu WT; Liu FC; Chen HC; Chou YC; Sun CA
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35329085
[TBL] [Abstract][Full Text] [Related]
7. Dose-Dependent Proton Pump Inhibitor Exposure and Risk of Type 2 Diabetes: A Nationwide Nested Case-Control Study.
Kuo HY; Liang CS; Tsai SJ; Chen TJ; Chu CS; Chen MH
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886592
[TBL] [Abstract][Full Text] [Related]
8. Identification of the Components of Proton Pump Inhibitors and Potassium-Competitive Acid Blocker That Lead to Cardiovascular Events in Working-Age Individuals: A 12-Month Retrospective Cohort Study Using a Large Claims Database.
Watanabe A; Momo K; Tanaka K; Uchikura T; Kiryu Y; Niiyama K; Kodaira N; Matsuzaki A; Sasaki T
Biol Pharm Bull; 2022; 45(9):1373-1377. PubMed ID: 36047207
[TBL] [Abstract][Full Text] [Related]
9. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Caro JJ; Salas M; Ward A
Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
Lu S; Zhao J; Chen X; Xu S; Yang X; Zhang Y; Ma Z; Jiang H; Zhou H
Chem Biol Interact; 2022 Dec; 368():110219. PubMed ID: 36243147
[TBL] [Abstract][Full Text] [Related]
11. Association of Increased Risk of Pneumonia and Using Proton Pump Inhibitors in Patients With Type II Diabetes Mellitus.
Lin WL; Muo CS; Lin WC; Hsieh YW; Kao CH
Dose Response; 2019; 17(2):1559325819843383. PubMed ID: 31080379
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study.
Czarniak P; Ahmadizar F; Hughes J; Parsons R; Kavousi M; Ikram M; Stricker BH
Br J Clin Pharmacol; 2022 Jun; 88(6):2718-2726. PubMed ID: 34907592
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors for chronic obstructive pulmonary disease.
Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
[TBL] [Abstract][Full Text] [Related]
14. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study.
Kim MG; Im YJ; Lee JH; Kim EY; Yeom SW; Kim JS
Front Med (Lausanne); 2022; 9():1076356. PubMed ID: 36714137
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease.
Chen CH; Lin HC; Lin HL; Lin YT; Chou JM; Hsu SP; Fung CP
J Microbiol Immunol Infect; 2015 Aug; 48(4):390-6. PubMed ID: 24291618
[TBL] [Abstract][Full Text] [Related]
16. Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults.
Ma Y; Li S; Yang H; Zhang Y; Li H; Zhou L; Lin J; Chen Y; Hou Y; Zhang X; Liu T; Zhou X; Wang Y
Atherosclerosis; 2022 Oct; 358():47-54. PubMed ID: 36113328
[TBL] [Abstract][Full Text] [Related]
17. The bidirectional association between type 2 diabetes and psoriasis: Two retrospective cohort studies.
Chiu HY; Hung CJ; Muo CH; Fan KC; Sung FC
Indian J Dermatol Venereol Leprol; 2020; 86(4):366-374. PubMed ID: 32031110
[TBL] [Abstract][Full Text] [Related]
18. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
19. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study.
Lei WY; Wang JH; Yi CH; Liu TT; Hung JS; Wong MW; Bair MJ; Vaezi MF; Orr WC; Chen CL
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101397. PubMed ID: 32224118
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.
Klotz U
Int J Clin Pharmacol Ther; 2006 Jul; 44(7):297-302. PubMed ID: 16961157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
